Skip to main content

Table 1 Patient demographics and baseline characteristics (pooled population)

From: Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies

Parameter Placebo Glycopyrrolate Aclidinium Total
  (n = 149) 3 μg BID
(n = 91)
6.25 μg BID
(n = 92)
12.5 μg BID
(n = 145)
25 μg BID
(n = 54)
50 μg BID
(n = 149)
100 μg BID
(n = 59)
400 μg BID
(n = 94)
(N = 378)
Mean (SD) age, years 57.7 (7.65) 54.5 (5.90) 54.4 (5.90) 56.9 (7.37) 59.6 (8.98) 56.4 (7.49) 59.4 (7.65) 54.6 (5.92) 59.0 (8.05)
Age <65 years, n (%) 120 (80.5) 89 (97.8) 90 (97.8) 124 (85.5) 40 (74.1) 126 (84.6) 42 (71.2) 92 (97.9) 278 (73.5)
Gender, n (%)
 Female 80 (53.7) 49 (53.8) 49 (53.3) 76 (52.4) 30 (55.6) 73 (49.0) 34 (57.6) 50 (53.2) 197 (52.1)
 Male 69 (46.3) 42 (46.2) 43 (46.7) 69 (47.6) 24 (44.4) 76 (51.0) 25 (42.4) 44 (46.8) 181 (47.9)
Race, n (%)
 White 131 (87.9) 81 (89.0) 83 (90.2) 132 (91.0) 51 (94.4) 135 (90.6) 49 (83.1) 84 (89.4) 339 (89.7)
 Black/African American 17 (11.4) 10 (11.0) 9 (9.8) 13 (9.0) 3 (5.6) 13 (8.7) 10 (16.9) 10 (10.6) 37 (9.8)
 American Indian/Alaskan Native 1 (0.7) 0 0 0 0 1 (0.7) 0 0 2 (0.5)
Post-bronchodilator FEV1, n (%)
  <50% predicted 60 (40.3) 34 (37.4) 34 (37.0) 59 (40.7) 28 (51.9) 62 (41.6) 25 (42.4) 35 (37.2) NA
  ≥50% predicted 89 (59.7) 57 (62.6) 58 (63.0) 86 (59.3) 26 (48.1) 87 (58.4) 34 (57.6) 59 (62.8) NA
  1. BID twice daily, FEV 1 forced expiratory volume in 1 s, NA not available, SD standard deviation